Stocktoria
Taysha Gene Therapies, Inc. TSHA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-24
Taysha Gene Therapies, Inc. statistics & valuation
Market cap$1.8B
P / B7.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1130.6% | -1097.6% | -468.8% | -6492.7% | — |
| Net margin | -1115.3% | -1071.6% | -722.1% | -6635.3% | — |
| FCF margin | -960.1% | -979.2% | -497.6% | -4356.9% | — |
| Return on assets | -31.7% | -55.7% | -64.6% | -131.5% | -81.6% |
| Return on equity | -44.1% | -124.8% | -148.9% | -17493.6% | -183.0% |
| Debt / equity | 0.20× | 0.61× | 0.54× | 40.01× | 0.39× |
| Current ratio | 12.23 | 5.42 | 4.08 | 1.54 | 3.08 |
| Revenue growth | 17.3% | -46.1% | 517.5% | — | — |
Source: SEC EDGAR filings · CIK 0001806310 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.